Accentia Biopharmaceuticals, Inc. (Accentia) is a biotechnology company that is developing Cyrevia as a system of care for the treatment of autoimmune diseases. The Company is also developing the SinuNasal Lavage System as a medical device for the treatment of chronic sinusitis. Additionally, through the Company�s, subsidiary, Biovest International, Inc., it is developing BiovaxID as a therapeutic cancer vaccine for treatment of non-Hodgkin�s lymphoma (NHL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) and other B-cell cancers and AutovaxID, for the production of a broad range of patient-specific medicines, such as BiovaxID and for various vaccines, including vaccines for influenza and other contagious diseases. In December 2011, the Company completed the sale of its business unit, Analytica International, Inc., a healthcare economics consulting firm.